ATE232090T1 - Orale pharmazeutische zusammensetzungen die pantoprazol mit verzögerter freisetzung und antimikrobielle mittel enthalten - Google Patents

Orale pharmazeutische zusammensetzungen die pantoprazol mit verzögerter freisetzung und antimikrobielle mittel enthalten

Info

Publication number
ATE232090T1
ATE232090T1 AT96924849T AT96924849T ATE232090T1 AT E232090 T1 ATE232090 T1 AT E232090T1 AT 96924849 T AT96924849 T AT 96924849T AT 96924849 T AT96924849 T AT 96924849T AT E232090 T1 ATE232090 T1 AT E232090T1
Authority
AT
Austria
Prior art keywords
oral pharmaceutical
pharmaceutical compositions
sustained release
compositions containing
antimicrobial agents
Prior art date
Application number
AT96924849T
Other languages
English (en)
Inventor
Rango Dietrich
George Sachs
Hartmut Ney
Gerald Benedikt
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE232090T1 publication Critical patent/ATE232090T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96924849T 1995-07-05 1996-07-02 Orale pharmazeutische zusammensetzungen die pantoprazol mit verzögerter freisetzung und antimikrobielle mittel enthalten ATE232090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/498,386 US5945124A (en) 1995-07-05 1995-07-05 Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
PCT/EP1996/002892 WO1997002020A1 (en) 1995-07-05 1996-07-02 Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole

Publications (1)

Publication Number Publication Date
ATE232090T1 true ATE232090T1 (de) 2003-02-15

Family

ID=23980878

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02005081T ATE324872T1 (de) 1995-07-05 1996-07-02 Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
AT96924849T ATE232090T1 (de) 1995-07-05 1996-07-02 Orale pharmazeutische zusammensetzungen die pantoprazol mit verzögerter freisetzung und antimikrobielle mittel enthalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02005081T ATE324872T1 (de) 1995-07-05 1996-07-02 Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern

Country Status (14)

Country Link
US (3) US5945124A (de)
EP (2) EP0841903B1 (de)
JP (1) JPH11508577A (de)
AT (2) ATE324872T1 (de)
AU (1) AU6517496A (de)
CA (2) CA2587000A1 (de)
CY (1) CY2459B1 (de)
DE (2) DE69636104T2 (de)
DK (2) DK0841903T3 (de)
ES (2) ES2192226T3 (de)
HK (1) HK1010836A1 (de)
PT (2) PT1213015E (de)
SI (1) SI0841903T1 (de)
WO (1) WO1997002020A1 (de)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69631981T2 (de) * 1995-09-21 2005-04-14 Pharma Pass Ii Llc, Irvine Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE69827392T2 (de) * 1997-07-25 2005-10-27 Altana Pharma Ag Protonenpumpenhemmer als kombinationstherapeutika mit antibakteriell wirkenden substanzen
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
CA2305762C (en) * 1997-10-09 2006-09-26 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6362169B1 (en) * 1998-02-24 2002-03-26 Kaneka Corporation Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
CA2325050A1 (en) * 1998-04-06 1999-10-14 Dalhousie University A novel nitroreductase and therapeutic uses therefor
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
ATE321538T1 (de) 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
IL142629A0 (en) 1998-11-18 2002-03-10 Astra Ab Improved chemical process and pharmaceutical formulation
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
DE10030318C1 (de) * 2000-06-27 2002-02-28 Byk Gulden Lomberg Chem Fab Arzneimittelverpackung für die Eradikationstherapie
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AU2002231654A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical paste comprising an acid-labile active ingredient
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IL158991A0 (en) * 2001-06-22 2004-05-12 Pfizer Prod Inc Pharmaceutical compositions comprising low-solubility and/or acid sensitive drugs and neutralized acidic polymers
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US20030175342A1 (en) * 2002-03-14 2003-09-18 Karl Kolter Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
DE10211289A1 (de) 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
CA2480824A1 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
BR0312347A (pt) * 2002-07-05 2005-04-12 Temrel Inc Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
WO2004009059A1 (en) * 2002-07-19 2004-01-29 Aventis Pharma S.A. Taste masked oral composition of telithromycin
JP2005538105A (ja) * 2002-07-25 2005-12-15 ファルマシア・コーポレーション 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
EP1530460A2 (de) * 2002-08-16 2005-05-18 Themis Laboratories Private Limited Herstellungsverfahren für eine benzimidazole enthaltende stabile orale pharmazeutische darreichungsform des typs "multiple units"
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1558211A2 (de) * 2002-10-30 2005-08-03 Pharmacia Corporation Orale tabletten mit verlängerter freisetzung und verfahren für deren herstellung sowie verwendung derselben
WO2004058228A1 (en) * 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
EP1603537A4 (de) * 2003-02-20 2009-11-04 Santarus Inc Neuartige formulierung, antazidkomplex-immediatfreisetzung für eine schnelle und anhaltende unterdrückung von magensäure
EP1602362B1 (de) * 2003-03-12 2016-09-28 Takeda Pharmaceutical Company Limited Arzneimittelzusammensetzung mit wirkstoff, der in hoher konzentration an einem kugelförmigen kern anhaftet
CA2520321A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
BR0300882A (pt) * 2003-04-09 2005-05-10 Cmax Otimizacao De Resultados Composições farmacêuticas, método e uso de formulação para tratamento e prevenção de infecções associadas com helicobacter pylori em mamìferos e no ser humano
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (de) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
EP1653924A4 (de) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
CA2547398A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
CA2565083C (en) 2004-05-07 2014-07-08 Altana Pharma Ag Novel pharmaceutical dosage form and manufacturing process
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP1845982A2 (de) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Durch ein nichtwässriges schichtungsverfahren hergestellte stabile orale benzimidaziol-zusammensetzungen
JP2008534530A (ja) * 2005-03-29 2008-08-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形
KR20080002789A (ko) * 2005-03-29 2008-01-04 에보니크 룀 게엠베하 조절 물질의 전달에 영향을 미치는 매트릭스를 가지는펠렛을 포함하는 다중 미립자 제약 형태
CA2608444A1 (en) * 2005-05-13 2007-03-15 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1803450A1 (de) 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmazeutische Zusammensetzungen zur Eradikation von Helicobacter Pylori
WO2007080601A1 (en) * 2006-01-16 2007-07-19 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
JP5649784B2 (ja) * 2006-02-07 2015-01-07 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 組成物、基材を組成物でコーティングする方法、被覆基材、製品、フィルム、ペレット、タブレット及びカプセル
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026768B1 (de) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Pharmazeutische formulierung auf mehreren einheiten
WO2008015530A2 (en) * 2006-08-03 2008-02-07 Aurobindo Pharma Limited Stable solid oral formulation of pantoprazole
CN101484147B (zh) * 2006-08-18 2015-07-08 赢创罗姆有限责任公司 对于具有水中良好溶解性的活性成分具有受控的活性成分释放性的药物组合物
US8173158B2 (en) 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
CA2704826A1 (en) * 2007-11-27 2009-06-04 Ohara Pharmaceutical Co., Ltd. Method for producing granulated preparation
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
NZ592049A (en) * 2008-10-03 2012-11-30 Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
DE102008056312A1 (de) 2008-11-07 2010-05-12 Biogenerics Pharma Gmbh Verwendung von Mikrotabletten als Lebens-und Futtermittelzusatz
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
US8663671B2 (en) 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20150283083A1 (en) * 2012-11-19 2015-10-08 Azanta A/S Dispersible Tablet
JP5934835B2 (ja) * 2013-03-08 2016-06-15 富士フイルム株式会社 腸溶性細粒及び医薬組成物
US20140271845A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Coated substrate compositions
US20160331688A1 (en) * 2014-01-31 2016-11-17 Shionogi & Co., Ltd. Sustained release formulation
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
EP0695123A4 (de) * 1993-04-27 1996-09-11 Sepracor Inc Verfahren und zusammensetzungen zur behandlung gastrischer störungen unter verwendung optisch reinen pantoprazols
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
WO1995008332A1 (en) * 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I

Also Published As

Publication number Publication date
ES2192226T3 (es) 2003-10-01
DK0841903T3 (da) 2003-05-19
CA2587000A1 (en) 1997-01-23
ES2263700T3 (es) 2006-12-16
ATE324872T1 (de) 2006-06-15
US6274173B1 (en) 2001-08-14
EP1213015A1 (de) 2002-06-12
AU6517496A (en) 1997-02-05
PT841903E (pt) 2003-06-30
US6068856A (en) 2000-05-30
EP0841903A1 (de) 1998-05-20
US5945124A (en) 1999-08-31
CA2232450A1 (en) 1997-01-23
DE69626116D1 (de) 2003-03-13
DE69636104D1 (de) 2006-06-08
PT1213015E (pt) 2006-09-29
EP1213015B1 (de) 2006-05-03
JPH11508577A (ja) 1999-07-27
DK1213015T3 (da) 2006-08-14
DE69626116T2 (de) 2003-10-23
HK1010836A1 (en) 1999-07-02
DE69636104T2 (de) 2006-11-30
CA2232450C (en) 2007-09-04
SI0841903T1 (en) 2003-08-31
CY2459B1 (en) 2005-06-03
EP0841903B1 (de) 2003-02-05
WO1997002020A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
ATE232090T1 (de) Orale pharmazeutische zusammensetzungen die pantoprazol mit verzögerter freisetzung und antimikrobielle mittel enthalten
ATE232091T1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung von reversiblen protonpumpen-inhibitoren
ATE477793T1 (de) Eine im mund schnell zerfallende tablette
NO975872D0 (no) Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter
TR200001810A3 (tr) Hemen Eriyen Oral Dozaj Formülasyonu.
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
CA2029046A1 (en) Sustained release compositions for treating periodontal disease
DE69532415D1 (de) Schmelzextrudierte oral verabreichbare opioidformulierungen
NO971206D0 (no) Forlenget-frigjöringsformulering
DE69520882D1 (de) Arzneizubereitung enthaltend amoxycillin und kaliumclavunalat
ES2051782T3 (es) Una composicion farmaceutica de liberacion lenta.
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
DK0770384T3 (da) Faste, vandfrie farmaceutiske sammensætninger til vaginal anvendelse
CA2225628A1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
ITMI931822A1 (it) Composizioni farmaceutiche a base di nimesulide, somministrabili per via orale, non gastrolesive e/o a rilascio controllato

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0841903

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee